AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04136366
Drug: ADX-2191 (intravitreal methotrexate 0.8%)
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy
Trial: NCT02669264
Drug: ADCT-402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT03850509
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPS-2071-matched placebo, tablets, orally, BID.
Trial: NCT05178355
Drug: KVD824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active
Trial: NCT05178355
Drug: Placebo to KVD824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04052867
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An equivalent volume of normal saline is given
Trial: NCT03948243
Drug: Caffeine 100 MG
RxNorm normalized name: caffeine 100 MG
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: probe substrate
Trial: NCT03808337
Drug: Systemic Therapy/Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist. For patients randomized to receive SBRT, systemic therapy can be continued during SBRT at the discretion and concensus of treating physicians (medical oncologist and radiation oncologist). If the treating physicians recommend discontinuing systemic therapy during SBRT, general guidelines for stopping and reinitiating systemic regimen are as follows: Hormonal therapies and immunotherapy can be continued during SBRT. Consideration can be given to holding cytotoxic chemotherapy beginning 3 to 7 days prior to the initiation of SBRT until 3 to 7 days after the completion of SBRT. Similarly, consideration can be given to holding biologic agents during SBRT and for 0 to 3 days before and after.
Trial: NCT02876094
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose-response
Trial: NCT00957684
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily placebo comparator
Trial: NCT01967173
Drug: Flovent Diskus® 100 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flovent is an ICS
Trial: NCT01967173
Drug: Flovent Diskus® 250 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flovent is an ICS
Trial: NCT01967173
Drug: Flovent Diskus® 500 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flovent is an ICS
Trial: NCT01967173
Drug: Advair Diskus® 100/50 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advair is an ICS/LABA combination
Trial: NCT01967173
Drug: Advair Diskus® 250/50 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advair is an ICS/LABA combination
Trial: NCT02096679
Drug: AZD9291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteer will receive a single oral dose of 20 mg \[14C\]-AZD9291 as a solution on Day 1
Trial: NCT03819465
Drug: MEDI5752
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI5752 IV Every 3 weeks (q3w)
Trial: NCT00546559
Drug: statins (simvastatin, pravastatin)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03819465
Drug: AZD2936
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2936 IV
Trial: NCT01046253
Drug: Prevacid®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Delayed-Release Capsule
Trial: NCT02739997
Drug: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
Trial: NCT01101009
Drug: Perindopril + amlodipine + if necessary, hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two perindopril 4 mg tablets + 1 amlodipine 10 mg tablet + placebo tablet matching the olmesartan/amlodipine tablet. All tablets are taken once daily. The duration of administration of perindopril tablets and placebo is 24 weeks. The duration of administration of amlodipine tablets is 24-26 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
Trial: NCT01101009
Drug: olmesartan/amlodipine + hydrochlorothiazide, if necessary.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan/amlodipine tablets 40 mg/10 mg, + placebo tablets matching the perindopril tablet and amlodipine tablet. All tablets are taken once daily for 24 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
Trial: NCT00492531
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
Trial: NCT03382275
Drug: Iron Supplement
RxNorm normalized name: Iron supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: any oral or intravenous prescription iron supplement
Trial: NCT03384745
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains no active drug.
Trial: NCT04050488
Drug: Zinc Sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At the age of 3 days or priming\> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing zinc (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
Trial: NCT04050488
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the age of 3 days or priming\> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing placebo (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
Trial: NCT01824251
Drug: NPB-01
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05728632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, capsule, once daily, for 12 months
Trial: NCT00579878
Drug: Methotrexate-Sulfasalazine-Hydroxychloroquine
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methotrexate:~dosing starts at 10mg/week (4 tabs/wk). If total remission (according to ACR criteria found in Appendix II) has not been achieved and the labs are acceptable at the 8-week evaluation, the dose increased to 15 mg/week (6 tabs/wk);at the 16-week evaluation, the dose increased to 20 mg/week (8 tabs/wk). This dose will remain stable until the end of the study.~Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable,dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day).
Trial: NCT01048333
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Diskus and Placebo Turbuhaler
Trial: NCT03008460
Drug: Eziclen®/Izinova®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution taken the evening before the colonoscopy
Trial: NCT03008460
Drug: Klean-Prep®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution taken the evening before the colonoscopy
Trial: NCT00317954
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01182142
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1,250 mg/m2 orally twice a day, days 1-14
Trial: NCT01361568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single i.v. dose administered preoperatively
Trial: NCT01361568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single i.v. dose administered postoperatively for pain
Trial: NCT04786938
Drug: Saccharomyces Boulardii-Containing Product in Oral Dose Form
RxNorm normalized name: Saccharomyces boulardii-containing product in oral dose form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. boulardii CNCM I-745 (approximately 22.5 x109 CFU)
Trial: NCT02197273
Drug: Standard of care analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02247245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04187105
Drug: Arm1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive the following standard conditioning regimen:~Fludarabine 30 mg/m2 IVPB daily from Day -6 (6 days before stem cell infusion) through Day -2
Trial: NCT04187105
Drug: Arm1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV cyclophosphamide 14.5 mg/kg intravenously prior to transplant on Days -6 and -5.
Trial: NCT04187105
Drug: Arm1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus IV initially in doses of 0.15 mg/kg/day for 3 days, followed by conversion to oral therapy (0.15 mg/kg twice daily)
Trial: NCT00365352
Drug: XP13512 600MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP13512 600MG ONCE DAILY
Trial: NCT00365352
Drug: XP13512 1200MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP13512 1200MG ONCE DAILY
Trial: NCT00365352
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLACEBO ONCE DAILY
Trial: NCT02106975
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention
Trial: NCT01272973
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral) administered once daily for 10 weeks.
Trial: NCT02168127
Drug: Drug: PRC-063
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate Hydrochloride Extended-Release Capsules
Trial: NCT02168127
Drug: PRC-063
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate Hydrochloride Extended-Release Capsules
Trial: NCT01209052
Drug: GSK1325756
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug will be orally administered in varying amounts over varying time periods as detailed in the 'arms' section.
Trial: NCT00611507
Drug: Oxaliplatin, 5-Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5FU 500 mg/m² per week in IV bolus infusion during 30 min AF 20mg/m²/week in infusion, during 10-20 minutes prior 5FU infusion; Eloxatin 85 mg/m² as IV infusion 2-6 hours, every 2 weeks. Three weeks of treatment, one week rest.
Trial: NCT03617679
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants allocated to the placebo arm will receive a placebo tablet (that looks identical to the active ingredient tablet) twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Tablet should be taken around the same time every day, with 8 or more ounces of water.
Trial: NCT04187105
Drug: Arm1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide on days 3 and 4 after transplant at a dose of 50mg/kg per day
Trial: NCT01357421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single iv dose of 0.9% sodium chloride for injection USP
Trial: NCT02416752
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The remifentanil infusion was used intra operatively in remifentanil group and intermittent boluses of morphine or fentanyl administered for conventional opioid group
Trial: NCT01174511
Drug: A -1 Cool Cream,Vaselin ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A- 1 Cool Cream applied to flexural aspects of the upper and lower limb on the one site of patient and placebo (Vaseline ointment) applied to other site of the upper and lower limb in the itch patient. Applying the ointment will be a regular time, twice a day for 5 consecutive days
Trial: NCT00890253
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 1mg per kg body weight starting within 24 hours after transplantation. Then q24 but with reduction by 5 mg every 48 hours until maintenance dose of 7.5 mg
Trial: NCT00918047
Drug: SPN-804O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open Label study
Trial: NCT00722800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet daily for 24 weeks
Trial: NCT00169533
Drug: GW572016 oral tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib either at 750, 1000, 1250 or 1500 mgs
Trial: NCT01516151
Drug: Lipid Lowering Medication
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will be treated as per the Standard of care.
Trial: NCT03592693
Drug: Combined Vitamin C and Stress-Dose Hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
Trial: NCT04180150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a treatment which is designed to have no therapeutic value.
Trial: NCT02470026
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single control treatment
Trial: NCT00282178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT00931879
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
Trial: NCT00282412
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Causes prevention of cell division by forming adducts with DNA
Trial: NCT00282412
Drug: Campath 1H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: humanized monoclonal antibody against CD52 antigen
Trial: NCT02221024
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00928837
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: non-steroidal anti-inflammatory drug
Trial: NCT00820352
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo twice a day for 12 weeks
Trial: NCT00734474
Drug: LY2189265
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00734474
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00734474
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00785928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (SC) every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
Trial: NCT03325296
Drug: LEO 124249
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ointment containing LEO 124249
Trial: NCT02470039
Drug: insulin 338 (GIPET I)
RxNorm normalized name: insulin isophane, human Injectable Suspension [Humulin I]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administered once daily in combination with metformin with or without DPP-4 inhibitor
Trial: NCT02470039
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once daily
Trial: NCT03294538
Drug: Generic Estradiol Vaginal Cream USP, 0.01%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal cream, generic formulation of the brand product.
Trial: NCT03294538
Drug: Estrace® Vaginal Cream USP, 0.01%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal cream, brand product.
Trial: NCT03329118
Drug: SHR3824, Simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
Trial: NCT00493623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo i.v. single dose
Trial: NCT00493623
Drug: ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg i.v. single dose
Trial: NCT00534625
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of placebo
Trial: NCT00235469
Drug: SPM 927
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03286738
Drug: FOLFIRI, target agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Bevacizumab~* Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Cetuximab
Trial: NCT00689780
Drug: AZD1940
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution Multiple ascending dose given orally once daily at day 1-12
Trial: NCT06558097
Drug: XXB750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single SC dose of XXB750 (administered by single or multiple injections)
Trial: NCT00449072
Drug: TAA-AQ, Nasacort® AQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 110 μg TAA-AQ was administered once daily intranasally (1 spray delivering 55 μg of TAA-AQ in each nostril) during the double-blind treatment period
Trial: NCT00449072
Drug: Claritin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were provided Children's Claritin® Syrup (5 mg of loratadine per 5 mL), as rescue medication for the relief of allergic rhinitis (AR) symptoms, and could be used throughout the study on an as needed basis according to the Food and Drug Administration-approved manufacturer's label
Trial: NCT00792948
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00792948
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00730522
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, bid, 12 weeks
Trial: NCT02410525
Drug: [11C]PF-06427878
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration via intravenous infusion of 20 ug \[11C\]PF-06427878 on Day 1 of all 3 Periods
Trial: NCT02410525
Drug: PF-06427878 10 mg
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral administration of 10 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to \[11C\]PF-06427878 administration
Trial: NCT00792948
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00792948
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or IT
Trial: NCT04261036
Drug: Ascorbic Acid 1000 mg
RxNorm normalized name: ascorbic acid 1000 MG
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg ascorbic acid (Vitamin C) for 14 days post-op after an elective gynecological surgery.
Trial: NCT01645800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo capsule: Three times daily for 52 weeks.
Trial: NCT02322346
Drug: Group LL
RxNorm normalized name: CELECOXIB N-DES(BENZENESULFONAMIDE) 200 mg ORAL CAPSULE [Truemed Group LLC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritonsillar infiltration with low-dose of levobupivacaine 0.25%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour.
Trial: NCT01557647
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo inhalation solution
Trial: NCT02322346
Drug: Group HL
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritonsillar infiltration with high dose of levobupivacaine 0.5%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour.
Trial: NCT04337268
Drug: saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion for 60 min.